Selank Research Overview

Selank is a synthetic heptapeptide developed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G with a long history in immunological research. The additional amino acids in Selank were added to improve stability relative to tuftsin itself.

It is studied primarily in behavioral neuroscience and neurochemistry models in rodents, and to a much smaller extent in clinical research conducted in Russia.

Tuftsin was characterized in the 1970s for its activity in immune cell assays. Its rapid degradation limited its usefulness as an experimental tool, prompting the design of analogues.

Selank was developed at a Russian research institute as one such analogue. Most published research on it originates from Russian institutions, and the compound has no approved status in the United States.

Neurochemical studies in rodents have examined monoamine systems — serotonin, dopamine, and noradrenaline metabolism — and markers associated with GABAergic signaling. These are correlative measurements of neurotransmitter turnover, and a specific receptor target for Selank has not been established.

Other work has examined expression of brain-derived neurotrophic factor (BDNF) and gene expression profiles in rat brain tissue, as well as enkephalin-degrading enzyme activity, proposed as a route by which the peptide might influence endogenous peptide signaling.

Immunological readouts inherited from the tuftsin literature, such as cytokine expression, have also been measured.

Behavioral neuroscience — anxiety-related behavioral models in rodents.

Neurochemistry — monoamine and GABA-associated measures.

Gene expression research in brain tissue.

Neurotrophic factor research, including BDNF measures.

Immune signaling, following from tuftsin research.

Most Selank findings come from rodent behavioral and neurochemical experiments.

A limited number of clinical studies have been published in Russia, generally small and not conducted under the reporting standards typical of large international trials. They are not sufficient to establish clinical conclusions, and independent replication outside that setting is lacking.

No controlled trial evidence from international regulatory-grade programs exists, and Selank is not an approved medicine in the United States.

Geographic and institutional concentration of the literature, with limited independent replication.

No established molecular target, which limits mechanistic interpretation.

Small clinical studies with limited methodological detail available in indexed sources.

Sparse long-term data of any kind.

Selank is a synthetic tuftsin analogue studied mainly in rodent behavioral and neurochemical models.

Reported effects on monoamine systems, BDNF, and gene expression are preliminary and mechanistically unresolved.

The limited regional clinical literature should not be treated as equivalent to established clinical evidence.

This page is provided for scientific and educational purposes only. It summarizes published laboratory research and does not constitute medical advice, does not describe any approved therapy, and does not provide instructions for human use of any kind.

SFVLAB supplies this compound strictly as a research-use-only material for laboratory investigation.